Ye Jingmei, Wang Jiani, Zhang Nana, Liu Yu, Tan Li, Xu Lihua
Department of Blood Transfusion, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China.
Breast Cancer Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China.
Oncol Lett. 2018 May;15(5):7182-7190. doi: 10.3892/ol.2018.8202. Epub 2018 Mar 7.
The aim of the present study was to investigate the expression of transactivation response RNA-binding protein (TARBP)1 and its clinical significance in human non-small-cell lung cancer (NSCLC). TARBP1 expression at the mRNA level was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in 10 NSCLC tissues and paired adjacent normal tissues. TARBP1 protein expression was analyzed in 90 paraffin-embedded NSCLC tissue samples and paired adjacent normal tissues by immunohistochemistry. Statistical analyses were performed to assess the clinicopathological significance of TARBP1 expression. The expression of TARBP1 mRNA was higher in the 10 NSCLC samples than in the paired adjacent non-tumor tissues (P=0.0017). In the paraffin-embedded tissue samples, the expression level of TARBP1 was higher in the cancer tissues than in the adjacent non-cancerous tissues. TARBP1 expression was detected in 76.67% (69/90) of the NSCLC samples and in 22.22% (20/90) of the adjacent normal lung tissues (P<0.001). The expression of TARBP1 was significantly associated with histological grade (P<0.001), clinical stage (P=0.024) and pathological type (P<0.001), along with a decreased overall survival (OS) rate (P<0.001). On multivariate analysis, the expression of TARBP1 was an independent prognostic factor for hazard ratio (OS, 2.729; 95% confidence interval, 1.471-5.061; P=0.003). TARBP1 is overexpressed in NSCLC, and the expression of TARBP1 is associated with pathological grade, clinical stage and pathological type. Thus, TARBP1 may be an independent prognostic marker in patients with NSCLC.
本研究旨在探讨反式激活应答RNA结合蛋白（TARBP）1在人非小细胞肺癌（NSCLC）中的表达及其临床意义。采用逆转录-定量聚合酶链反应（RT-qPCR）检测10例NSCLC组织及其配对的癌旁正常组织中TARBP1 mRNA水平的表达。采用免疫组织化学方法分析90例石蜡包埋的NSCLC组织样本及其配对的癌旁正常组织中TARBP1蛋白的表达。进行统计学分析以评估TARBP1表达的临床病理意义。10例NSCLC样本中TARBP1 mRNA的表达高于配对的癌旁非肿瘤组织（P = 0.0017）。在石蜡包埋组织样本中，癌组织中TARBP1的表达水平高于癌旁非癌组织。76.67%（69/90）的NSCLC样本和22.22%（20/90）的癌旁正常肺组织中检测到TARBP1表达（P < 0.001）。TARBP1的表达与组织学分级（P < 0.001）、临床分期（P = 0.024）和病理类型（P < 0.001）显著相关，总生存率（OS）降低（P < 0.001）。多因素分析显示，TARBP1的表达是危险比的独立预后因素（OS，2.729；95%置信区间，1.471 - 5.061；P = 0.003）。TARBP1在NSCLC中过表达，其表达与病理分级、临床分期和病理类型相关。因此，TARBP1可能是NSCLC患者的独立预后标志物。
